Eli Lilly and Company
https://www.lilly.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eli Lilly and Company
Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s
The US FDA approved Lilly’s Kisunla (donanemab) for early Alzheimer’s disease and the anti-amyloid antibody will launch into a challenging market primed by Eisai/Biogen’s Leqembi.
Lilly’s Kisunla: Labeling Allows For Stopping Treatment Based On Amyloid Plaque Reduction
However, the US FDA’s approval of donanemab comes with little guidance on when to stop treatment or when the anti-amyloid agent may need to be restarted in Alzheimer’s patients.
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
US FDA’s Dry July? Few Goal Dates Portend Quiet Month For Approvals
Sun’s deuruxolitinib and Novo Nordisk’s insulin icodec stand out as new molecular entities among the small cluster of US FDA user fee goal dates in July.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Akouos, Inc.
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- Disarm Therapeutics, Inc.
- Hypnion
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- Protomer Technologies
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice